港股异动 | 医渡科技(02158)涨超14% AI有望赋能临床试验 附属中标SMR001滴眼液III期临床研究项目

智通财经
Yesterday

智通财经APP获悉,医渡科技(02158)尾盘涨超14%,截至发稿,涨12.89%,报6.57港元,成交额4.66亿港元。

消息面上,医渡科技近期公布,公司联属公司天津开心生活科技有限公司中标山东衍渡生物科技有限公司重组人神经生长因子(SMR001)滴眼液Ⅲ期临床研究项目,项目总金额约为人民币5582万元。

值得注意的是,9月16日,2025腾讯数字生态大会医疗专场召开。医渡科技高级解决方案专家施成发表“AI赋能临床试验全流程”主题演讲,结合医渡科技多年技术沉淀与实践案例,从技术支撑、场景落地到生态构建,全面阐释了AI切实提升临床试验效率与质量的路径,推动行业高质量发展。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10